have shown that in the human lung cancer cell line, A549, the combinedtreatment of Rosi and Gefitinib was more beneficial than Gefitinib treatment alone[24].Taken together, these data provide support that the upregulation of PTEN levelswith Rosi treatment may reverse the Gefitinib resistance in these patients.Such a treatment could have the potential to be advantageous to patients withboth sporadic and familial cancer. Here, PTEN is linked to lung cancer.